

PFIZER STATEMENT ON PhRMA-EFPIA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING

July 24, 2013

The Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have published new commitments for responsible data sharing practices by biopharmaceutical companies [to read these commitments, visit <http://onphr.ma/18yru3e> .] The new commitments are designed to expand access to clinical trial data and advance science. They propose ways of sharing data that will protect patient privacy, respect the regulatory process, and preserve incentives to undertake novel medical research for the benefit of patients. We believe the solutions offered by PhRMA and EFPIA provide a responsible alternative to other approaches currently being discussed in Europe.

Pfizer has been an active partner and supporter in the development of these industry commitments, which we fully support and will adhere to in our policies and practices. We have been and continue to be aligned with the actions outlined in the commitments as part of our ongoing efforts to optimize the use of our clinical data to further medical research and improve the quality of health care. Many of our practices already meet or exceed the standards established by PhRMA and EFPIA.

- Pfizer participates in numerous data sharing initiatives, publishes all clinical trial results within 18 months of study completion, and provides existing clinical data in response to legitimate requests from researchers and regulators.
- We also have been a leader in making results available and accessible to clinical trial participants and will continue to expand our sharing of information in meaningful ways to inform and empower patients.

We are currently reviewing our policies to ensure they fully reflect the new commitments. An update to our public disclosure policy will be issued later this year. We welcome this opportunity to reaffirm Pfizer's dedication to ensuring that the data collected in the trials we conduct are appropriately used in the service of public health.

####